Serum IL-2 receptor levels by response
. | . | Serum IL-2 receptor levels, U/mL* . | . | . | |
|---|---|---|---|---|---|
| Patient no. . | Rituximab response (no. of doses) . | Before therapy . | After therapy (months after start of therapy) . | Disease status (mo) . | |
| 1 | CR | > 5868 | 4184 (2) | CR (44+) | |
| < 24 (5) | |||||
| 553 (8) | |||||
| 587 (12) | |||||
| 663 (16) | |||||
| 498 (20) | |||||
| 723 (24) | |||||
| 904 (28) | |||||
| 713 (44) | |||||
| 2 | CR | > 6432 | 419 (4) | CR (32+) | |
| 300 (8) | |||||
| 3 | CR | > 5868 | < 24 (5) | CR (45+) | |
| 4 | CR | > 5868 | 429 (4) | CR (30+) | |
| 454 (12) | |||||
| 5 | CR | 2895 | 939 (1) | CR (33+) | |
| 585 (2) | |||||
| 470 (6) | |||||
| 6 | CR | 16 509 | 664 (2) | CR (23+) | |
| 456 (9) | |||||
| 7 | CR | 5364 | 1586 (2) | PD (18) | |
| 1195 (9) | |||||
| 8 | CR (12) | > 5868 | 1775 (3) | CR (40+) | |
| 9 | CR-RD | 5645 | 575 (3) | PD (12) | |
| 1889 (12) | |||||
| 10 | CR-RD (4) | 2957 | 982 (5) | PD (23) | |
| 2078 (13) | |||||
| 2316 (15) | |||||
| 11 | PR (4) | > 5868 | ND (—) | PD (39) | |
| 12 | PR (12) | 20 468 | 23 106 (1) | ||
| 23 640 (2) | PD (8) | ||||
| 77 827 (6) | |||||
| 13 | NR | > 6684 | > 6684 (1) | NA | |
| 14 | NR (6) | > 6684 | > 6684 (12) | NA | |
| 15 | NR (4) | > 5868 | 4845† (1) | SD (24+) | |
. | . | Serum IL-2 receptor levels, U/mL* . | . | . | |
|---|---|---|---|---|---|
| Patient no. . | Rituximab response (no. of doses) . | Before therapy . | After therapy (months after start of therapy) . | Disease status (mo) . | |
| 1 | CR | > 5868 | 4184 (2) | CR (44+) | |
| < 24 (5) | |||||
| 553 (8) | |||||
| 587 (12) | |||||
| 663 (16) | |||||
| 498 (20) | |||||
| 723 (24) | |||||
| 904 (28) | |||||
| 713 (44) | |||||
| 2 | CR | > 6432 | 419 (4) | CR (32+) | |
| 300 (8) | |||||
| 3 | CR | > 5868 | < 24 (5) | CR (45+) | |
| 4 | CR | > 5868 | 429 (4) | CR (30+) | |
| 454 (12) | |||||
| 5 | CR | 2895 | 939 (1) | CR (33+) | |
| 585 (2) | |||||
| 470 (6) | |||||
| 6 | CR | 16 509 | 664 (2) | CR (23+) | |
| 456 (9) | |||||
| 7 | CR | 5364 | 1586 (2) | PD (18) | |
| 1195 (9) | |||||
| 8 | CR (12) | > 5868 | 1775 (3) | CR (40+) | |
| 9 | CR-RD | 5645 | 575 (3) | PD (12) | |
| 1889 (12) | |||||
| 10 | CR-RD (4) | 2957 | 982 (5) | PD (23) | |
| 2078 (13) | |||||
| 2316 (15) | |||||
| 11 | PR (4) | > 5868 | ND (—) | PD (39) | |
| 12 | PR (12) | 20 468 | 23 106 (1) | ||
| 23 640 (2) | PD (8) | ||||
| 77 827 (6) | |||||
| 13 | NR | > 6684 | > 6684 (1) | NA | |
| 14 | NR (6) | > 6684 | > 6684 (12) | NA | |
| 15 | NR (4) | > 5868 | 4845† (1) | SD (24+) | |
CR indicates complete remission; PD, progressive disease requiring further therapy; CR-RD, CR with residual marrow hairy cells 1% to 5%; ND, not done, NR, no response; NA, not applicable, and SD, stable disease.
Reference range, less than 970 U/mL or 200 to 1100 U/mL (depending on assay); for conversion to pg/mL, multiply by factor of 8.85
Marrow hairy cells unchanged with improvement of platelet count